Overview

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Status:
Active, not recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase:

Phase 2

Details

Lead Sponsor:

Acerta Pharma BV

Treatments:

Acalabrutinib